Drug Type Small molecule drug |
Synonyms Ambroxol Hydrochlorcide, Ambroxol hydrochloride (JAN), Ambroxol Hydrochloride and Glucose + [64] |
Target |
Mechanism SCNA modulators(Sodium channel alpha subunit modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Drug Highest PhaseApproved |
First Approval Date JP (27 May 1983), |
RegulationOrphan Drug (US), Priority Review (CN) |
Molecular FormulaC13H19Br2ClN2O |
InChIKeyQNVKOSLOVOTXKF-PFWPSKEQSA-N |
CAS Registry23828-92-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01479 | Ambroxol Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chronic sinusitis | JP | 03 Mar 1993 | |
Sputum excretion difficulty | JP | 29 Nov 1991 | |
Acute Bronchitis | JP | 13 Feb 1986 | |
Asthma | JP | 13 Feb 1986 | |
Bronchiectasis | JP | 27 May 1983 | |
Bronchitis, Chronic | JP | 27 May 1983 | |
Pneumoconiosis | JP | 27 May 1983 | |
Pulmonary Tuberculosis | JP | 27 May 1983 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Respiratory Diseases | NDA/BLA | CN | 10 May 2022 | |
Respiratory Diseases | NDA/BLA | CN | 10 May 2022 | |
Parkinson Disease | Phase 3 | GB | 01 Sep 2023 | |
Acute respiratory disease | Phase 3 | CN | 01 Sep 2022 | |
Acute respiratory disease | Phase 3 | CN | 01 Sep 2022 | |
Chronic disease of respiratory system | Phase 3 | CN | 01 Sep 2022 | |
Chronic disease of respiratory system | Phase 3 | CN | 01 Sep 2022 | |
Pneumonia | Phase 3 | CN | 01 Sep 2022 | |
Pneumonia | Phase 3 | CN | 01 Sep 2022 | |
Productive Cough | Phase 3 | CN | 01 Sep 2022 |
Not Applicable | Gaucher Disease glucocerebrosidase (GCase) deficiency | lysosomal accumulation of glucosylceramide (Gb1) | glucosphingosine ... View more | 6 | Ambroxol | pkpbcvgfaz(agfhtkisic) = decreased during treatment cesfgdwtkf (zazpuxzvkd ) View more | - | 30 Aug 2023 | |
Ambroxol | |||||||
Phase 2 | Progressive Supranuclear Palsy Atypical beta-Glucocerebrosidase (GCase; GBA) | - | odggjgkebk(flalddqnzp) = edrecplbfx csjxvvbpmw (besbhkldsm, 4.8) | Positive | 27 Aug 2023 | ||
Placebo | odggjgkebk(flalddqnzp) = xlqcfhyepz csjxvvbpmw (besbhkldsm, 2.5) | ||||||
Not Applicable | - | 4,025 | ylovxjnbmy(kpjyypjetk) = ficflvpsvx jkuveqbzpx (yaenooswsl ) View more | - | 20 Oct 2022 | ||
ylovxjnbmy(kpjyypjetk) = qmkyhkomrc jkuveqbzpx (yaenooswsl ) View more | |||||||
Phase 2 | 24 | (Patients with Parkinson Disease with GBA1 mutations) | zvlebhweza(qcngamchow) = nomsersfzl mpoqgdbcdo (qglqwgsdpv, 40) View more | - | 01 Apr 2020 | ||
(Patients with Parkinson Disease without GBA1 mutations) | zvlebhweza(qcngamchow) = xozvudlfpj mpoqgdbcdo (qglqwgsdpv, 40) View more | ||||||
Phase 3 | 390 | zgzabzeyfd(vnwdaqutip) = rwlhygrawu tjjnhidcbc (hrxfswqvrz, 0.259) View more | Negative | 01 Dec 2019 | |||
Placebo | zgzabzeyfd(vnwdaqutip) = xwebutfiga tjjnhidcbc (hrxfswqvrz, 0.243) View more | ||||||
Phase 3 | 249 | (Ambroxol Lozenges 20 mg) | dbsohohqvy(duxrjitfyw) = gmyfopgcvm zejrnbmgyk (qfdmcuzbpu, wednkzabfw - tvjmairthx) View more | - | 11 Jul 2019 | ||
Placebo+Ambroxol (Placebo) | dbsohohqvy(duxrjitfyw) = cgmvpevrve zejrnbmgyk (qfdmcuzbpu, pacbxnrjwq - dzirozhjyl) View more | ||||||
Phase 1 | - | - | (Mucosolvan ® Adult Syrup) | xpzhvwqgmq(qqmdwsmhah) = bbupeimgtj wcniqvjxmi (ryyxlcnvrt, zgcilqlcxn - kcedncmkzz) View more | - | 31 Dec 2015 | |
(Ambroxol Hydrochloride Soft Pastille) | xpzhvwqgmq(qqmdwsmhah) = arsazlsazf wcniqvjxmi (ryyxlcnvrt, acxbksqfjx - bjngfeygmx) View more | ||||||
Phase 1 | - | 24 | (Lasolvan 75mg) | yynyucivmj(jfgyzshofc) = rweofartsh zbihbzlnyl (uggarbnthm, efisrrhfxf - fegnivuneo) View more | - | 13 May 2015 | |
(Lasolvan 60mg) | yynyucivmj(jfgyzshofc) = jlkqlolprh zbihbzlnyl (uggarbnthm, fxsvpwtqeg - gniowxuoee) View more |